Stocks and Investing Stocks and Investing
Thu, September 28, 2023
Wed, September 27, 2023
Tue, September 26, 2023
Mon, September 25, 2023

Brian Cheng Maintained (BCAB) at Buy with Decreased Target to $14 on, Sep 25th, 2023


Published on 2024-10-28 06:33:33 - WOPRAI, Brian Cheng
  Print publication without navigation


Brian Cheng of JP Morgan, Maintained "BioAtla, Inc." (BCAB) at Buy with Decreased Target from $17 to $14 on, Sep 25th, 2023.

Brian has made no other calls on BCAB in the last 4 months.



There are 3 other peers that have a rating on BCAB. Out of the 3 peers that are also analyzing BCAB, 0 agree with Brian's Rating of Hold.



These are the ratings of the 3 analyists that currently disagree with Brian


  • Arthur He of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $17 on, Wednesday, August 2nd, 2023
  • Reni Benjamin of "JMP Securities" Reiterated at Buy and Held Target at $12 on, Wednesday, August 2nd, 2023
  • Tony Butler of "EF Hutton" Reiterated at Strong Buy and Held Target at $25 on, Wednesday, August 2nd, 2023